ScoreHaematology

BALL score for relapsed/refractory CLL

Classifies previously treated chronic lymphocytic leukaemia patients into three survival risk groups.

Updated 30 October 2026

When to use it

Relapsed or refractory CLL before starting a new line, with targeted therapy (BTKi, idelalisib, venetoclax) or chemoimmunotherapy.

What it needs

  • Serum β2-microglobulin ≥ 5 mg/LYes or no
  • Anaemia: haemoglobin < 110 g/L (women) or < 120 g/L (men)Yes or no
  • LDH above the upper limit of normalYes or no
  • Less than 24 months since starting the last therapyYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

BALL score
ResultInterpretation
≤ 1Low risk (2-year survival ≈ 90 %)
2–3Intermediate risk (2-year survival ≈ 80 %)
≥ 4High risk (2-year survival ≈ 56 %)

Practical tip

It uses only routine data (β2-microglobulin, haemoglobin, LDH and start date of last therapy), without genetic testing.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top